Case report of a very late dual coronary stent thrombosis in a patient with coronavirus disease 2019. Issue 6 (7th June 2021)

• Record Type: Journal Article
• Authors: Hauguel-Moreau, Marie; Lannou, Simon; Bergez, Léa; Mansencal, Nicolas
• Editors: Karamasis, Grigoris; Stathogiannis, Konstantinos; Vrachatis, Dimitrios A; Kanakakis, John; Phan, Derek; Sayers, Max; Thomson, Ross
• Is Part Of: European heart journal. Volume 5:Issue 6(2021)
• Publication Date: 2021-06-07
• Subjects: COVID-19 -- Stent thrombosis -- ST-segment elevation myocardial infarction -- Case report; Cardiology -- Periodicals; Cardiology -- Case studies -- Periodicals; Heart -- Diseases -- Periodicals; Heart -- Diseases -- Case studies -- Periodicals; 616.12
• DOI: 10.1093/ehjcr/ytab114
• Languages: English
• ISSNs: 2514-2119

Abstract

Abstract: Background : Coronavirus disease 2019 (COVID-19) is associated with hypercoagulability and a high rate of thrombosis. Few cases of coronary stent thrombosis associated with COVID-19 have been reported. Case summary : In this report, we describe the case of a 65-year-old man with a history of coronary artery disease (CAD) who was admitted following an out-of-hospital cardiac arrest related to an ST-segment elevation myocardial infarction revealing a very late dual coronary stent thrombosis of the left anterior descending and posterior descending arteries. Ten days prior to admission, he was diagnosed with COVID-19 pneumonia and treated with dexamethasone, which led to rapid clinical improvement. After resuscitation, coronary angiography revealed an acute thrombotic occlusion in the two previous drug-eluting stents (implanted in 2010 and 2018), with a high thrombus burden. He was successfully treated by percutaneous coronary intervention. The patient did not present any further complications during his hospital stay and was transferred to a cardiac rehabilitation centre. Discussion : Dual stent thrombosis is an exceptional event highlighting the high procoagulant state promoted by coronavirus 19. This case suggests that strengthening of antithrombotic therapy in CAD patients presenting with COVID-19 should be discussed.